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A novel matrix assisted laser desorption/ionization (MALDI)-based mass spectrometric
approach has been evaluated to rapidly analyze a custom designed PEGylated peptide that is
31 residues long and conjugated with 20 kDa linear polyethylene glycol (PEG) at the side chain
of Lys. MALDI-TOF MS provided sufficiently high resolution to allow observation of each of
the oligomers of the heterogeneous PEGylated peptide (m/m of ca. 500), while a typical
ESI-MS spectrum of this molecule was extremely complex and unresolved. Reflector in-source
decay (reISD) analysis using MALDI-TOF MS was attempted to identify the PEGylation site at
intact molecular level without any sample treatment. An reISD spectrum of the free peptide
was observed with abundant c-, y-, and [z 2]-fragment ion series, whereas, in the fragmented
PEGylated peptide, the fragment ion series were truncated at the residue where PEG was
attached. Therefore, a direct comparison of these top-down reISD spectra suggested the
location of the PEGylation site. Results from this study demonstrate a clear analytical utility of
the ISD technique to characterize structural aspects of heterogeneous biomolecules. (J Am
Soc Mass Spectrom 2009, 20, 326–333) © 2009 American Society for Mass SpectrometryAsignificant challenge is associated with devel-opment of biomolecules into effective therapeu-tic use due to their limited chemical and phys-
ical stability. In particular, short plasma half-life of
biotherapeutics may lead to poor efficacy in humans,
and, therefore, developing methods to achieve longer
circulation times at low dosage volumes is required. To
obtain such improved stability, biomolecules can be
chemically modified. One of the most successful ap-
proaches currently employed is to covalently attach
inert, nontoxic, and nonantigenic polymers, such as
polyethylene glycol (PEG), to active molecules, a strat-
egy termed PEGylation [1–6]. Due to its favorable
properties, PEG is approved by FDA [5] for oral, in-
jection, and dermal administration to humans. PEGylation
technology has been successfully developed and ap-
plied to achieve prolonged in vivo circulation of
biomolecules in the body for effective potency, as
demonstrated by a series of marketed PEGylated ther-
apeutics, including Neulasta®, or pegfilgrastim [5, 7, 8].
Typically, the conjugation of PEG of ca. 20 kDa or
larger to biotherapeutics has proven efficient by provid-
ing desired stability [4, 9, 10]. However, tremendous
analytical challenges are associated with studying such
heterogeneous molecules [11], where confident deter-
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doi:10.1016/j.jasms.2008.10.013mination of the PEGylation site is one of the important
requirements to fully characterize and understand
PEGylated molecules. Previously, several groups have
reported on the identification of the site at which PEG
was conjugated [12], where PEG of relatively small size
were commonly used [13–15]. Due to a lower degree of
polymerization associated with smaller PEG, an analy-
sis was readily performed in these cases. Also, these
studies mostly involved enzymatic digestions to selec-
tively analyze the smaller fragments bearing potential
PEGylation sites by mass mapping. Although this
bottom-up approach may provide useful information, it
has a disadvantage of resulting in excessive numbers of
peptides to complicate analysis. This issue becomes
more serious when the biomolecules to be PEGylated
are of large size, as it is usually the case for many
biotherapeutics, and contain multiple potential conju-
gation sites. Also, from practical point of view, this
procedure involves lengthy sample preparations that
are prone to sample loss, resulting in reduced sensitiv-
ity. Therefore, it is most ideal to be able to study these
types of molecules in their intact forms without any
chemical or enzymatic modifications.
Matrix assisted laser desorption/ionization mass
spectrometry (MALDI-MS) has been widely accepted as
a useful means to study various types of biomolecules
due to its soft ionization properties [16, 17]. Unlike
electrospray ionization (ESI) that produces multiply
charged ions, the MALDI process almost exclusively
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327J Am Soc Mass Spectrom 2009, 20, 326–333 DETERMINATION OF PEGYLATION SITE USING ISDgenerates singly charged ions [18], which can greatly
help reduce complexity of mass spectra for easier and
more confident data interpretation. MALDI is most
conveniently combined with a time-of-flight (TOF)
mass analyzer that can provide sufficiently high-
resolution and mass accuracy in a wide achievable mass
range to resolve large heterogeneous molecules [19].
Due to its remarkable sensitivity, low sample consump-
tion, ease of sample preparation, and high-throughput
capability, MALDI-TOF MS has also been successfully
used for the analysis of synthetic polymers [20–23].
Further advancement has led to the development of
MALDI-TOF/TOF MS [24–26], which has been exten-
sively used in proteomics applications for characteriz-
ing biomarkers and important post-translational
modifications (PTMs) [27–30]. In addition, its reflec-
tor in-source decay (reISD) capability enabled the top-
down analysis of intact proteins.
In-source decay (ISD), a unique fragmentation tech-
nique available with MALDI-MS [31–35], is a fast frag-
mentation process occurring at the nanosecond time
scale inside the source region, rapidly following the
laser shot [36]. According to Takayama’s model, the
formation of the specific c and z ions in ISD spectra
arises from hydrogen radical transfer from matrix to
analyte [37–39], inducing fragmentation at the position
where the transfer occurs. Therefore, ISD fragmentation
does not exhibit any preference for labile bonds but
occurs uniformly across the protein sequence and can
be advantageous by generating relatively simple frag-
ment ion spectra even from large proteins. Previously,
ISD has been shown to be useful in determining pri-
mary structure of biomolecules [35]. ISD tends to work
very efficiently for analyzing large molecules, as re-
cently demonstrated in the study of intact proteins and
its applications also included the characterizations of
PTMs, such as disulfide bonds and phosphorylation
[25, 31, 36]. Based on the unique mechanism by which
ISD occurs and the fact that modifications usually
remain intact during this fragmentation process for the
purpose of identification and localization [31], it ap-
pears that ISD can be useful to study purposely modi-
fied biomolecules, such as PEGylated peptides, at the
intact molecular level. In this work, we present prelim-
inary findings obtained for the determination of a
PEGylation site by ISD analysis using a custom con-
structed PEGylated peptide as a model compound with-
out any chemical or enzymatic treatments.
Experimental
Materials
An in-house synthesized peptide that consists of 31
amino acids has been purified and conjugated to poly-
ethylene glycol at Amgen Inc. (Thousand Oaks, CA). As
previously described [40], both termini of this peptide
remain blocked by acetylation at the N-terminus and
-NH2 at the C-terminus. The sequence consists of thefollowing: Ac-WVTHR*LAGLLSR*SGGVVK*K19
NFVPTDVGPXAF-NH2, where 20 kDa linear mPEG-
aldehyde (Sunbright; NOF Corp., Tokyo, Japan) was
conjugated at the Lys19 residue through the -amino
group. R*, K*, and X represent non-natural amino acids
incorporated for citrulline, homoArg, and naphthyl-
Ala, respectively.
Trifluoroacetic acid (TFA) was obtained from J. T.
Baker (Phillipsburg, NJ), formic acid from Riedel-de
Haen (Morristown, NJ), and acetonitrile from Burdick
and Jackson (Morristown, NJ). DI water was purified
using Milli-Q system (18.2 M · cm; Millipore, Billerica,
MA). Sinapinic acid, 2,5-dihydroxybenzoic acid (DHB),
and the MALDI peptide calibration standard were
obtained from Bruker Daltonics (Bremen, Germany)
and used without further purifications. A PEG standard
of 22 kDa used for the MALDI analysis was from
Polymer Standards Service (Mainz, Germany). Metha-
nol and ethanol were purchased from Sigma-Aldrich
(Deissenhofen, Germany).
ESI-LTQ Orbitrap MS Analysis
A small particle-packed reversed-phase HPLC column
(Zorbax SB-C18, 2.1  100 mm, 1.8 m; Agilent Tech-
nologies, Palo Alto, CA) was used to obtain high-
resolution separation. Chromatographic analysis was
performed using an Agilent 1100 HPLC system oper-
ated at a flow rate of 0.2 mL/min with a column
temperature controlled at 40 °C. The mobile phase was
comprised of 0.05% TFA and 0.05% formic acid in 100%
DI water for A and in 100% acetonitrile for B. The
following gradient profile was used: 10% to 30% B in 10
min, 30% to 55% B in 35 min, 55% to 100% B in 2 min,
hold at 100% B for 1 min, 100% to 10% B in 1 min, and
hold at 10% B for 16 min. Approximately 5 g of the
PEGylated peptide was loaded onto the column. UV
detection was monitored at 215 nm. The HPLC was
interfaced directly to an LTQ Orbitrap MS equipped
with an ESI source (Thermo, San Jose, CA) for the
acquisition of mass spectra using Xcalibur software
(version 2.0 SR1; Thermo). The 20 kDa PEG sample,
prepared at a concentration of 1 g/mL in DI water,
was directly infused into the LTQ Orbitrap MS via ESI
at a flow rate of 10 L/min. The LTQ Orbitrap is a
hybrid high-resolution MS configured with a linear ion
trap as a front end for setting MS parameters and an
electrostatic orbital ion trap as a back end for the
acquisition of mass spectra of high-resolution and high
accuracy. Connecting the two components of the mass
spectrometer is a curved linear trap, or C-trap, which is
used to store and condition ions for introduction into
the Orbitrap mass analyzer.
MALDI-MS Analysis and Data Interpretation
For the acquisition of the MALDI spectrum of the
PEGylated peptide, a sinapinic acid “crystal seed” prep-
aration method was used. From a saturated solution of
(a) 2
328 YOO ET AL. J Am Soc Mass Spectrom 2009, 20, 326–333sinapinic acid prepared in ethanol, a thin-layer was
formed on a stainless steel MALDI target plate. The
PEGylated peptide was dissolved in 50% methanol/
50% water at a concentration of 1 mg/mL and mixed at
Figure 1. ESI-linear ion trap MS spectrum of
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329J Am Soc Mass Spectrom 2009, 20, 326–333 DETERMINATION OF PEGYLATION SITE USING ISD10% acetonitrile was used as a matrix. The free peptide
of 500 fmol/L and the PEGylated peptide prepared
above were each mixed with DHB, where 2 L of each
of these mixtures was spotted onto a target plate.
A Bruker Ultraflex III MALDI-TOF/TOF MS equip-
ped with 200 Hz solid-state smartbeam laser [41],
LIFT-TOF/TOF assembly, and gridless ion reflector [25]
was used for all MALDI MS measurements. ReISD
spectra were obtained as previously described [25, 33].
In general, increased laser fluence, delayed extraction,
and the choice of matrix are critical for the formation of
ISD fragment ions. Six thousand to 8000 single laser
shots were acquired for each reISD spectrum. External
calibration of the spectra was carried out using PEG of
22 kDa for the analysis of intact PEGylated peptide and
a peptide calibration standard for reISD fragmented
PEGylated peptide. Spectra were acquired and pro-
cessed using the Compass 1.2 software package (Bruker
Daltonics). BioTools version 3.0 was used for the top-
down sequencing analysis of the peptides.
Figure 3. reISD MALDI MS spectrum obtaine
citrulline; K* for homoArg). Matching fragment
Table 1. List of ISD fragment ions and their theoretical monoiso
masses)
R* Ser Gly Gly V
Ion 12 13 14 15 1
c 1451.81 175
 0.10
y 1487.77 1657.88 1756.95 185
 0.14 0.12 0.13
z2 1472.76 1642.87 1741.94 184
 0.15 0.11 0.13
Asn Lys K* Val V denotes the difference between the experimental and theoretical fragmenResults and Discussion
ESI-MS and MALDI-TOF MS Analysis of
PEGylated Peptide
In contrast to unmodified proteins, PEGylated biomol-
ecules generally show oligomeric distribution of the
polymer with mass differences of 44 Da between the
oligomers. Previously, MALDI-TOF MS has been
shown to be useful in resolving the polymeric distribu-
tions of various polymers and PEGylated molecules
conjugated with relatively small size PEG [14, 42–46],
where singly charged ions are formed and detector
saturation is not significant [23]. However, it is impor-
tant to be able to analyze and resolve PEGylated bi-
omolecules conjugated with PEG of large size, i.e., 20
kDa or higher, which have proven to have significant
therapeutic value.
Mass spectra obtained using the HPLC interfaced
on-line with Orbitrap MS for the 20 kDa linear PEG and
r the free peptide used for PEGylation (R* for
are assigned.
masses (Da) for the free peptide (see Figure 3 for experimental
Val K* Lys Asn Phe
17 18 19 20 21
1851.02 2021.14 2149.24 2263.28 2410.35
0.05 0.12 0.07 0.11 0.15
1913.04 1970.06 2057.10 2214.18 2301.21
0.13 0.12 0.14 0.14 0.15
1898.03 1955.05 2042.09 2199.17 2286.20
0.09 0.12 0.12 0.15 0.16
Gly Gly Ser R* Serd fotopic
al
6
1.96
0.13
6.02
0.12
1.01
0.11
alt ion mass (R* for citrulline, K* for homoArg, and X for naphthyl-Ala).
330 YOO ET AL. J Am Soc Mass Spectrom 2009, 20, 326–333the PEGylated peptide are shown in Figure 1a and b,
respectively. Although attempts were made to obtain
high-resolution mass spectral data in the Orbitrap, the
size of the 20 kDa PEG and the PEGylated peptide
prevented it from traversing the C-trap, which is not
uncommon for the analysis of molecules of 20 kDa or
greater. Therefore, the spectra shown in Figure 1 were
actually acquired using the linear ion trap as a mass
analyzer. The spectra are extremely complex and unre-
solved due to the heterogeneity associated with a large
PEG, where the generation of multiply charged ions by
ESI has further complicated the spectra. This is a typical
observation for the ESI-MS analysis of PEGylated mol-
ecule, and interpretation of these spectra is essentially
unachievable.
Given that singly charged ions are preferentially
generated during the MALDI process, MALDI-TOF MS
can be useful for the study of heterogeneous molecules.
In addition, MALDI-MS is perhaps one of the most well
suited techniques to analyze polymers and polymer-
modified molecules because of the simplicity of the
mass spectra with hardly any unwanted fragmentation
occurring in the polymer moieties during ionization.
Figure 2 shows a representative mass spectrum from
the PEGylated peptide using linear MALDI-TOF MS,
where each of the oligomers can be clearly observed.
The number average molecular weight, Mn, of the
PEGylated peptide was determined to be 24,575 Da in
this experiment. In contrast to OH/H-terminated PEGs,
which are always observed as alkali-ionized species, the
PEGylated peptide was observed in its protonated form
in this experiment. However, only limited information
pertaining to the peptide part of the PEGylated mole-
cules can be obtained from MALDI-MS spectra alone.
Furthermore, the MS/MS analysis using collision-
induced dissociation (CID) for ion activation, although
generally possible for large molecules, is limited in this
case, as the fragmentation will mainly occur on the PEG
and provide little information on the peptide.
Determination of PEGylation Site Using reISD
PEGylation is generally carried out in a site-specific
manner to produce well defined bioconjugates using
numerous coupling strategies [7], and, therefore, it is
Table 1. Continued
Val Pro Thr Asp Val
22 23 24 25 26
2822.54 2921.61
0.10 0.04
2414.30 2527.38 2584.40 2655.44 2768.52
0.16 0.14 0.15 0.13 0.14
2399.29 2512.37 2569.39 2640.43 2753.51
0.17 0.11 0.18 0.16 0.18
Leu Leu Gly Ala Leuimportant to monitor and confirm that PEGylation was
successfully achieved at the desired locations. Previ-
ous studies have reported on the identification of the
PEGylation site using enzymatic digestions. Although
proteolytic digestion is a convenient means to study
large biomolecules that are difficult to analyze in intact
forms and often provides valuable information, it has a
number of limitations as described earlier. In particular,
as the molecule under the current study contains sev-
eral non-natural amino acids that have no known
enzymatic specificities, it would be difficult to correctly
assign mass mapping data upon proteolysis. Ideally,
determining the PEGylation site at the intact molecular
level, or top-down analysis, can effectively prevent
these problems and enable access to valuable informa-
tion retained in the intact form.
Shown in Figure 3 is an enlarged reflector ISD
spectrum obtained for the free peptide with [M  H]
of 3490.87 Da that was later PEGylated, where abun-
dant signals for c-, y-, and [z 2]-series of fragments, as
also listed in Table 1, were observed [33, 37]. Complete
sequence coverage of this model peptide was achieved
based on ISD sequencing analysis and the homoArg
[18], and the unmodified Lys19 residues were unequiv-
ocally assigned in the spectrum. Other fragmentation
techniques such as CID or post-source decay (PSD) [47]
using MALDI-MS often result in overwhelmingly de-
graded fragment products, including a-, d-, v, and
w-series, in addition to the more common b- and
y-series of fragment ions [26, 38]. CID fails to provide
reliable sequence readout at higher MW values, as the
labile peptide bonds are predominantly dissociated. In
contrast, ISD occurs uniformly across the sequence and
provides relatively simple fragment ion spectra that
generally include c- and (z  2)-series of fragment ions,
which result from the cleavage of N–C bonds on the
peptide backbone [39]. Although understanding of this
fragmentation mechanism is not complete, it has been
proposed that the process follows chemical activation
by hydrogen radical transfer reactions in the MALDI
plume. As a limitation, however, ISD-based MALDI-
TOF MS is a pseudo-MS/MS technique with in-source
fragmentation being incompatible with precursor ion
selection. This requires that the sample is highly pure or
Gly Pro X Ala Phe
27 28 29 30 31
3075.69
0.14
2925.61 3062.67 3163.72 3262.78 3490.87
0.15 0.09 0.06 0.13 0.11
2910.60 3047.66 3148.71 3247.77
0.17 0.17 0.17 0.14
R* His Thr Val Trp
331J Am Soc Mass Spectrom 2009, 20, 326–333 DETERMINATION OF PEGYLATION SITE USING ISDISD-MALDI MS to be combined with off-line chromato-
graphic separation.
Figure 4 shows an ISD spectrum obtained for the
protonated PEGylated peptide that uses the same free
peptide as above for conjugation. In the resulting frag-
ment ion spectrum, all fragment ions were observed in
the protonated forms, c- and y-series, as summarized in
Table 2; they clearly show a fragmentation pattern
comparable to that of the protonated free peptide.
However, the ion series for the PEGylated peptide were
observed to be truncated at Lys19 i.e., at c18 and y12,
respectively. This particular truncation of sequence
readout serves as a strong indication for the presence of
a modification at Lys19 here as the PEGylation site, in
which the PEG moiety of ca. 20 kDa is too large to be
monitored in the reISD spectra of the PEGylated pep-
tide. Based on high mass accuracy, as shown in Tables
1 and 2, and peak resolution in the range of 10,000 to
20,000 for reISD fragment peaks, this technique is
robust enough to detect, localize, and assign modifica-
tions of very small molecular mass differences, such as
deamidation.
Previously, it has been demonstrated that fragment
ion series using top-down ISD are truncated at the
position of cyclization, as in proline disulfide bonds [33,
36], and heme-crosslinks in cytochrome c [34]. Cycliza-
tion and large modifications introduced a gap or a
truncation in sequencing analysis, and, therefore,
helped predict the presence of such modifications. In
this experiment, PEG being a large and heterogeneous
molecule, MS sequencing information on Lys19 is miss-
ing as a result of PEG attachments. As fragments for the
modified side chains of proteins, such as phosphates,
glycans, or disulfide bonds, are typically not observed
in the spectra from ISD, ECD, and ETD, in contrast to
Figure 4. reISD-MALDI MS spectrum obtained
homoArg). Matching fragment ions are assigned.CID [30], the truncation of the ion series at Lys19 is in
line with the prediction that a conjugation with a 20 kDa
PEG would truncate the sequence readout at that par-
ticular position. It is believed that our observation
resembles the case of disulfide bonds characterization
or the study of proline containing sequences, where
their presence is characterized by missing sequencing
information due to the presence of cyclic moiety [32].
Recently, reductive treatment of the disulfides in pro-
teins by the use of reductive MALDI matrices [48] has
shown to remove the cyclic structures and enable the
direct sequence readout from the linearized protein.
The model compound studied in this preliminary
study may represent a relatively simple form of a
PEGylated molecule suitable for a straightforward anal-
ysis. It basically contains a single potential PEGylation
site, as the N-terminus of the peptide is acetylated and
not susceptible to the current PEGylation chemistry.
However, when the compounds to be studied have
added complexity in this regard, further study may
become necessary to validate the ability of the described
approach to distinguish different PEGylation sites and
quantify the respective degree of modification [48].
Nevertheless, the ISD-based approach presented in this
work has proven to be capable of rapidly suggesting the
PEGylation site of a PEGylated biomolecule by requir-
ing minimal sample preparation.
Conclusions
The ISD-based MALDI MS technique has already suc-
cessfully shown its usefulness for the structural study of
intact proteins and biologically occurring modifications
due to its unique ion fragmentation characteristics. The
work described herein suggests that applications of the
the PEGylated peptide (R* for citrulline; K* forfor
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332 YOO ET AL. J Am Soc Mass Spectrom 2009, 20, 326–333ISD can also be extended to study structural aspects of
PEGylated biotherapeutics. MALDI-MS is to play a
significant role in the development of polymers with
pharmaceutical significance due to its advantages de-
scribed earlier. MALDI-MS has a great potential to
rapidly provide very useful structural information from
heterogeneous molecules with clearly distinguishable
fragmentation properties of the different chemical moi-
eties. It is also important to emphasize that the entire
analysis was performed at the intact molecular level
without altering the original model compound, and,
therefore, dramatically improved throughput and sim-
plified data interpretation was achieved. Uniquely im-
portant for this application was the fact that no precur-
sor ion selection was necessary in reISD, which is not
possible with typical MS/MS experiments for mole-
cules exhibiting a high degree of polymerization at high
MW. ReISD spectra obtained in this work clearly pro-
vided detailed information about the sequence and
suggested the conjugation status of individual amino
acid residues in the PEGylated peptide.
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